Author index

A

Aarons L (*see* Simpson et al). 1999;66:474-84
Abernethy DR (*see* Donahue et al). 1999;66:563-68
Abiose AK (*see* Tangphao et al). 1999;66:232-8
Adams WP (*see* Singh et al). 1999;66:346-57
Agler D (*see* Swanson et al). 1999;66:294-305
Agren JJ (*see* Vidgren et al). 1999;66:315-22
Ahonen J (*see* Palkama et al). 1999;66:33-9
Ajayi F (*see* Yuan et al). 1999;66:9-15
Aljada A (*see* Dandona et al). 1999;66:58-65
Allen J (*see* Johnson et al). 1999;66:492-500
Alvarez JC, Gluck N, Arnulf I, Quintin P, Leboyer M, Pecquery R, Launay JM, Perez-Diaz F, Spreux-Varoquaux O. Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine. 1999;66:617-24
Amin RD (*see* Rogers et al). 1999;66:358-66
Antonijoan R (*see* Barbanoj et al). 1999;66:485-91
Aoyama N (*see* Tanigawara et al). 1999;66:528-34
Arnulf I (*see* Alvarez et al). 1999;66:617-24
Asada A (*see* Hamaoka et al). 1999;66:110-7
Atkinson AJ, Moore KE, Peck CC. Dr Marcus M. Reidenberg, recipient of the 1999 Harry Gold Award. 1999;66:1 (Commentary)
Aynacioglu AS, Sachse C, Bozkurt A, Kortunay S, Nacak M, Schröder T, Kayaalp O, Roots I, Brockmöller J. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. 1999;66:184-92

B

Backman JT (*see* Kivistö et al). 1999;66:444-53
Backman JT, Wang JS, Wen X, Kivistö KT, Neuvonen PJ. Mibeferadil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam. 1999;66:401-7
Badger GJ (*see* Petry et al). 1999;66:306-14
Balian JD (*see* Yuan et al). 1999;66:9-15
Ball SE, Scatnia JA, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of *CYP3A4*. 1999;66:288-94
Barbanoj M, Antonijoan R, Morte A, Grinyó JM, Solà R, Vallès J, Peraire C, Cordero JA, Muñoz A, Jané F, Obach R. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency. 1999;66:485-91
Barbey JT, Sale ME, Woosley RL, Shi J, Melikian AP, Hinderling PH. Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects. 1999;66:91-9
Barkvoll P (*see* Breivik et al). 1999;66:625-35
Barnas CR (*see* Krecic-Shepard et al). 1999;66:40-50
Bauer S (*see* Johne et al). 1999;66:338-45
Bauer S (*see* Sachse et al). 1999;66:431-8
Becquemont L (*see* Tennezé et al). 1999;66:582-8
Belz GG, Butzer R, Kober S, Mang C, Mutschler E. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. 1999;66:367-73
Benowitz NL (*see* Gelal et al). 1999;66:123-35
Bergquist C, Lindegard L. Dosing recommendations in liver disease. 1999;66:201 (Letter)
Bertilsson L (*see* Mirghani et al). 1999;66:454-60
Bertino JS (*see* Streetman et al). 1999;66:535-41
Bialer M (*see* Volosov et al). 1999;66:547-53
Bickel WK (*see* Petry et al). 1999;66:306-14
Bieglmayer C (*see* Pernerstorfer et al). 1999;66:51-7
Blaschke TF (*see* Tangphao et al). 1999;66:232-8
Blouin RA (*see* Poloyac et al). 1999;66:554-62
Blum RA (*see* Rogers et al). 1999;66:358-66
Boissel JP (*see* Nony et al). 1999;66:173-84
Bozkurt A (*see* Aynaciouglu et al). 1999;66:185-92
Brahmadevara N (*see* Mamidi et al). 1999;66:193-200
Breivik EK, Barkvoll P, Skovlund E. Combination of diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind, single-dose study. 1999;66:625-35
Brockmöller J (*see* Johne et al). 1999;66:338-45
Brockmöller J (*see* Sachse et al). 1999;66:431-8
Brockmöller J. (*see* Aynaciouglu et al). 1999;66:185-92
Brøsen K (*see* Sindrup et al). 1999;66:636-41
Brown MT (*see* Herman et al). 1999;66:374-9
Brunner HR (*see* Rossat et al). 1999;66:76-84
Bulzer R (*see* Belz et al). 1999;66:367-73
Bundschuh D (*see* Hartung et al). 1999;66:415-24
Burnett A (*see* Yuan et al). 1999;66:9-15
Burnier M (*see* Rossat et al). 1999;66:76-84
Burry AE (*see* Tan et al). 1999;66:275-81

C

Cadarso C (*see* de la Serna and Cadarso). 1999;66:166-72
Cai WM, Chen B, Zhou Y, Zhang YD. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers. 1999;66:516-21
Capparelli E (*see* Mirochnick et al). 1999;66:16-24
Chalon S (*see* Tangphao et al). 1999;66:232-8
Chavluvdi MR (*see* Mamidi et al). 1999;66:193-200
Chen B (*see* Cai et al). 1999;66:516-21
Chiba K (*see* Ikeda et al). 1999;66:265-74
Chiu HFK (*see* Lam et al). 1999;66:647 (Letter)
Chongsuphajaisiddhi T (*see* Simpson et al). 1999;66:474-84
Chorazyczewski J (*see* Tan et al). 1999;66:275-81
Chow L (*see* Lam et al). 1999;66:647 (Letter)
Clark AL (*see* Muir et al). 1999;66:85-90
Connor J (*see* Mirochnick et al). 1999;66:16-24
Cordero JA (*see* Barbanoj et al). 1999;66:485-91
Cucherat M (*see* Nony et al). 1999;66:173-84

D

d'Athis P (*see* Pariente-Khayat et al). 1999;66:136-9
Damodarram G (*see* Mamidi et al). 1999;66:193-200

July, pp. 1-104; August, pp. 105-210; September, pp. 211-332; October, pp. 333-444; November, pp. 445-546; December, pp. 547-674. Index to the ASCPT meeting abstracts is located in the February issue.

Dandona P, Mohanty P, Hamouda W, Aljada A, Kumbkarni Y, Garg R. Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study. 1999;66:58-65
Danish University Antidepressant Group. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. 1999;66:152-65
Davis DB (*see* Mould et al). 1999;66:246-57
de la Serna G, Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia. 1999;66:166-72
de Meijer A, Vollaard H, de Metz M, Verbruggen B, Thomas C, Novakova I. Meloxicam, 15 mg/day, spares platelet function in healthy volunteers. 1999;66:425-30
de Metz M (*see* de Meijer et al). 1999;66:425-30
Deinum HT (*see* van Lingen et al). 1999;66:509-15
Denolle T, Pellizzoni C, Jannuzzo G, Poggesi I. Hemodynamic effects of reboxetine in healthy male volunteers. 1999;66:282-7
Desel H (*see* Nau et al). 1999;66:25-32
Dettling M (*see* Sachse et al). 1999;66:431-8
Doecek WD (*see* Hartung et al). 1999;66:415-24
Donahue S, Flockhart DA, Abernethy DR. Ticlopidine inhibits phenytoin clearance. 1999;66:563-68

E

Echizen H (*see* Takahashi et al). 1999;66:569-81
Eichler HG (*see* Pernerstorfer et al). 1999;66:51-7
Elliott MJ(*see* Mould et al). 1999;66:246-57
Ellis RE (*see* Streetman et al). 1999;66:535-41
Endrenyi L (*see* Kalow et al). 1999;66:445-7 (Commentary)
Ericksson O (*see* Mirghani et al). 1999;66:454-60

F

Falk MC (*see* Johnson et al). 1999;66:492-500
Fantner F (*see* Hartung et al). 1999;66:415-24
Feinstein AR. Statistical reductionism and clinicians' delinquencies in humanistic research. 1999;66:211-7 (Commentary)
Feldman RD (*see* Tan et al). 1999;66:275-81
Ferron GM (*see* Ball et al). 1999;66:288-94
Fisher DM (*see* Shangraw et al). 1999;66:380-90
Fleishaker JC (*see* Herman et al). 1999;66:374-9
Flockhart DA (*see* Donahue et al). 1999;66:563-68
Flynn D (*see* Swanson et al). 1999;66:294-305
Foote MA (*see* Hartung et al). 1999;66:415-24
Forrest A (*see* Luzier et al). 1999;66:594-601
Franzen K (*see* Johnson et al). 1999;66:492-500
Fruncillo R (*see* Ball et al). 1999;66:288-94
Fujimura A (*see* Tsuruoka et al). 1999;66:609-16
Fujita M (*see* Murayama et al). 1999;66:258-64
Funck-Brentano (*see* Tennezé et al). 1999;66:582-8
Furuta T, Ohashi K, Kobayashi K, Iida I, Yoshida H, Shirai N, Takashima M, Kosuge K, Hanai H, Chiba K, Ishizaki T, Kaneko E. Effects of clarithromycin on the metabolism of omeprazole in relation to *CYP2C19* genotype status in humans. 1999;66:265-74

G

Gaedigk A (*see* Streetman et al). 1999;66:535-41
Gagliano KD (*see* Rogers et al). 1999;66:358-66
Garcia-Barcelo M (*see* Lam et al). 1999;66:647 (Letter)
Gardner BM (*see* Poloyac et al). 1999;66:554-62
Garg R (*see* Dandona et al). 1999;66:58-65
Gelal A, Jacob P, Yu L, Benowitz NL. Disposition kinetics and effects of menthol. 1999;66:128-35
Gerbeau C (*see* Kovarik et al). 1999;66:391-400
Geus WP (*see* Mathôt and Geus). 1999;66:140-51
Gluck N (*see* Alvarez et al). 1999;66:617-24
Gorski JC (*see* Krecic-Shepard et al). 1999;66:40-50
Gotschall R (*see* Streetman et al). 1999;66:535-41
Gramatté T, Oertal R. Intestinal secretion of intravenous talinolol is inhibited by luminal *R*-verapamil. 1999;66:239-45
Greenblatt DJ (*see* Tsunoda et al). 1999;66:461-71
Grinyó JM (*see* Barbanoj et al). 1999;66:485-91
Groopman JD (*see* Kinirons et al). 1999;66:224-31
Guerret M (*see* Kovarik et al). 1999;66:391-400
Guida M (*see* Ball et al). 1999;66:288-94
Guinta D (*see* Swanson et al). 1999;66:294-305
Gupta V (*see* van Agtmael et al). 1999;66:408-14
Gustafsson LL (*see* Mirghani et al). 1999;66:454-60

H

Haefeli WE (*see* Romerio et al). 1999;66:522-7
Hall J (*see* Ball et al). 1999;66:288-94
Hamaoka N, Oda Y, Hase I, Mizutani K, Nakamoto T, Ishizaki T, Asada A. Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. 1999;66:110-7
Hamouda W (*see* Dandona et al). 1999;66:58-65
Hanai H (*see* Ikeda et al). 1999;66:265-74
Hartung T, Doecek WD, Bundschuh D, Foote MA, Fantner F, Hermann C, Lenz A, Milwee S, Rich B, Simon B, Vook HD, von Aulock S, Wendel A. Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions. 1999;66:415-24
Hase I (*see* Hamaoka et al). 1999;66:110-7
He N (*see* Qin et al). 1999;66:642-6
Hellgren U (*see* Mirghani et al). 1999;66:454-60
Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. 1999;66:374-9
Hermann C (*see* Hartung et al). 1999;66:415-24
Hillis WS (*see* Muir et al). 1999;66:85-90
Hinderling PH (*see* Barbey et al). 1999;66:91-9
Hoffman BB (*see* Tangphao et al). 1999;66:232-8
Holroyd S, Seward RL. Psychotropic drugs in acute intermittent porphyria. 1999;66:323-5
Hopkins PJ (*see* Ball et al). 1999;66:288-94
Hotellier F (*see* Pariente-Khayat et al). 1999;66:136-9
Huang SL (*see* Qin et al). 1999;66:642-6
Hubert P (*see* Pariente-Khayat et al). 1999;66:136-9

I

Iida I (*see* Ikeda et al). 1999;66:265-74
Iinoue T (*see* Murayama et al). 1999;66:258-64
Ikeda Y (*see* Murayama et al). 1999;66:258-64
Ishizaki T (*see* Hamaoka et al). 1999;66:110-7
Ishizaki T (*see* Ikeda et al). 1999;66:265-74

J

Jacob P (*see* Gelal et al). 1999;66:123-35
Jané F (*see* Barbanoj et al). 1999;66:485-91
Jannuzzo G (*see* Denolle et al). 1999;66:282-7
Jensen TS (*see* Sindrup et al). 1999;66:636-41
Jilma B (*see* Pernerstorfer et al). 1999;66:51-7
Joensuu H (*see* Villikka et al). 1999;66:589-93
Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with a herbal extract from St John's wort (*Hypericum perforatum*). 1999;66:338-45

Johnson AG, Rigby RJ, Taylor PJ, Jones CE, Allen J, Franzen K, Falk MC, Nicol D. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. 1999;66:492-500
Jones CE (*see* Johnson et al). 1999;66:492-500
Jouvet P (*see* Pariente-Khayat et al). 1999;66:136-9

K

Kageyama H (*see* Koizumi et al). 1999;66:501-8
Kalow W, Ozdemir V, Tang BK, Tothfalusi L, Endrenyi L. The science of pharmacological variability: an essay. 1999;66:445-7 (Commentary)
Kaneko E (*see* Ikeda et al). 1999;66:265-74
Kao J (*see* Ball et al). 1999;66:288-94
Kapiotis S (*see* Pernerstorfer et al). 1999;66:51-7
Karhunen LJ (*see* Vidgren et al). 1999;66:315-22
Kasuga M (*see* Tanigawara et al). 1999;66:528-34
Katashima M (*see* Koizumi et al). 1999;66:501-8
Katneni K (*see* Mamidi et al). 1999;66:193-200
Kawaguchi A (*see* Tsuruoka et al). 1999;66:609-16
Kayaalp O (*see* Aynaciouglu et al). 1999;66:185-92
Kazierad DJ (*see* Luzier et al). 1999;66:594-601
Kearns GL (*see* Marshall and Kearns). 1999;66:66-75
Kearns GL (*see* Streetman et al). 1999;66:535-41
Kearns Gl (*see* Streetman et al). 1999;66:535-41
Killian A (*see* Luzier et al). 1999;66:594-601
Kim RB (*see* Kinirons et al). 1999;66:224-31
Kinirons MT, O'Shea D, Kim RB, Groopman JD, Thummel KE, Wood AJJ, Wilkinson RG. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. 1999;66:224-31
Kinitada S (*see* Murayama et al). 1999;66:258-64
Kita T (*see* Tanigawara et al). 1999;66:528-34
Kivistö KT (*see* Backman et al). 1999;66:401-7
Kivistö KT (*see* Lilja et al). 1999;66:118-27
Kivistö KT (*see* Villikka et al). 1999;66:589-93
Kivistö KT, Lilja JJ, Backman JT, Neuvonen PJ. Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride. 1999;66:444-53
Kobayashi K (*see* Ikeda et al). 1999;66:265-74
Kober S (*see* Belz et al). 1999;66:367-73
Koizumi F, Murakami M, Kageyama H, Katashima M, Terakawa M, Ohnishi A. Smoking accelerates absorption of inhaled elastase inhibitor FK706. 1999;66:501-8
Kolenda H (*see* Nau et al). 1999;66:25-32
Komada F (*see* Tanigawara et al). 1999;66:528-34
Kortunay S (*see* Aynaciouglu et al). 1999;66:185-92
Kosuge K (*see* Ikeda et al). 1999;66:265-74
Kovarik JM, Rigaudy L, Guerret M, Gerbeau C, Rost KL. Longitudinal assessment of a P-glycoprotein–mediated drug interaction of valspodar on digoxin. 1999;66:391-400
Krecic-Shepard ME, Barnas CR, Slimko J, Gorski JC, Wainer IW, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. 1999;66:40-50
Kubo S (*see* Takahashi et al). 1999;66:569-81
Kumbkarni Y (*see* Dandona et al). 1999;66:58-65
Kwok DC (*see* Mould et al). 1999;66:246-57

L

Laine K, Palovaara S, Tapanainen P, Manninen P. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. 1999;66:602-8
Lam K, Chow L, Leung T, Wing YK, Chiu HFK, Garcia-Barcelo M. Association between *CYP2A6* and *CYP2C19* mutant alleles. 1999;66:647 (Letter)
Langheinrich M (*see* Johne et al). 1999;66:338-45
Lassek C (*see* Nau et al). 1999;66:25-32
Launay JM (*see* Alvarez et al). 1999;66:617-24
Leboyer M (*see* Alvarez et al). 1999;66:617-24
Leeder S (*see* Streetman et al). 1999;66:535-41
Lemberger L. A flight through clinical pharmacology: it's great to soar with the eagles. 1999;66:218-23 (Commentary)
Lenz A (*see* Hartung et al). 1999;66:415-24
Lerner M (*see* Swanson et al). 1999;66:294-305
Lesko LJ (*see* Singh et al). 1999;66:346-57
Lesko LJ (*see* Yuan et al). 1999;66:9-15
Leung T (*see* Lam et al). 1999;66:647 (Letter)
Lilja JJ (*see* Kivistö et al). 1999;66:444-53
Lilja JL, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. 1999;66:118-27
Lindegard L (*see* Bergquist and Lindegard). 1999;66:201 (Letter)
Linder L (*see* Romerio et al). 1999;66:522-7
Liu L (*see* Rogers et al). 1999;66:358-66
Looareesuwan S (*see* Simpson et al). 1999;66:474-84
Luggen ME (*see* Mould et al). 1999;66:246-57
Luzier AB, Killian A, Wilton JH, Wilson MF, Forrest A, Kazierad DJ. Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. 1999;66:594-601

M

Macdonald CJ (*see* Tan et al). 1999;66:275-81
Madsen C (*see* Sindrup et al). 1999;66:636-41
Mäenpää H (*see* Villikka et al). 1999;66:589-93
Maillard M (*see* Rossat et al). 1999;66:76-84
Malikian AP (*see* Barbey et al). 1999;66:91-9
Mamidi RNVS, Satyavageeswaran S, Vakkalanka SVS, Chavluvdi MR, Katneni K, Brahmadevara N, Damodarram G, Subramaniam S. Polymorphism of dextromethorphan oxidation in South Indian subjects. 1999;66:193-200
Mang C (*see* Belz et al). 1999;66:367-73
Manninen P (*see* Laine et al). 1999;66:602-8
Marroum P (*see* Yuan et al). 1999;66:9-15
Marshall JD, Kearns GL. Developmental pharmacodynamics of cyclosporine. 1999;66:66-75
Mathôt RAA, Geus WP. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. 1999;66:140-51
Maurer A (*see* Johne et al). 1999;66:338-45
Mayer P (*see* Ball et al). 1999;66:288-94
McCann GP (*see* Muir et al). 1999;66:85-90
Milwee S (*see* Hartung et al). 1999;66:415-24
Minthorn EA (*see* Mould et al). 1999;66:246-57
Mirghani RA, Hellgren U, Westerberg PA, Ericksson O, Bertilsson L, Gustafsson LL. The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. 1999;66:454-60
Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies. 1999;66:16-24
Mizuntani K (*see* Hamaoka et al). 1999;66:110-7
Mohanty P (*see* Dandona et al). 1999;66:58-65
Mokhtari M (*see* Pariente-Khayat et al). 1999;66:136-9
Molzon JA (*see* Singh et al). 1999;66:346-57
Moore KE (*see* Atkinson et al). 1999;66:1 (Commentary)
Moreno HT (*see* Tangphao et al). 1999;66:232-8
Morte A (*see* Barbanoj et al). 1999;66:485-91

Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, Totoritis MC. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. 1999;66:246-57
Muir DF, McCann GP, Swan L, Clark AL, Hillis WS. Hemodynamic and coronary effects of intravenous eletriptan, a $5HT_{1B/1D}$-receptor agonist. 1999;66:85-90
Muller-Oerlinghausen B (*see* Sachse et al). 1999;66:431-8
Muñoz A (*see* Barbanoj et al). 1999;66:485-91
Murakami M (*see* Koizumi et al). 1999;66:501-8
Murayama N, Tanaka M, Kunitada S, Yamada H, Inoue T, Terada Y, Fjuita M, Ikeda Y. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers. 1999;66:258-64
Mutschler E (*see* Belz et al). 1999;66:367-73

N

Nacak M (*see* Aynaciouglu et al). 1999;66:185-92
Nafziger AN (*see* Streetman et al). 1999;66:535-41
Nakamoto T (*see* Hamaoka et al). 1999;66:110-7
Nau R, Desel H, Lassek C, Kolenda H, Prange H. Entry of tromethamine into the cerebrospinal fluid of humans after cerebrovascular events. 1999;66:25-32
Neuvonen PJ (*see* Backman et al). 1999;66:401-7
Neuvonen PJ (*see* Kivistö et al). 1999;66:444-53
Neuvonen PJ (*see* Lilja et al). 1999;66:118-27
Neuvonen PJ (*see* Palkama et al). 1999;66:33-9
Neuvonen PJ (*see* Villikka et al). 1999;66:589-93
Nicol D (*see* Johnson et al). 1999;66:492-500
Nony P, Cucherat M, Boissel JP. Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field. 1999;66:173-84
Nosten F (*see* Simpson et al). 1999;66:474-84
Novakova I (*see* de Meijer et al). 1999;66:425-30
Nussberger J (*see* Rossat et al). 1999;66:76-84

O

O'Shea D (*see* Kinirons et al). 1999;66:224-31
Obach R (*see* Barbanoj et al). 1999;66:485-91
Oda Y (*see* Hamaoka et al). 1999;66:110-7
Oertel R (*see* Gramatté and Oertel). 1999;66:239-45
Ohashi K (*see* Ikeda et al). 1999;66:265-74
Ohinishi A (*see* Koizumi et al). 1999;66:501-8
Ohmori M (*see* Tsuruoka et al). 1999;66:609-16
Okken A (*see* van Lingen et al). 1999;66:509-15
Okumura K (*see* Tanigawara et al). 1999;66:528-34
Olive G (*see* Pariente-Khayat et al). 1999;66:136-9
Olkkola KT (*see* Palkama et al). 1999;66:33-9
Ou-Yang DS (*see* Qin et al). 1999;66:642-6
Ozdemir V (*see* Kalow et al). 1999;66:445-7 (Commentary)

P

Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. 1999;66:33-9
Palovaara S (*see* Laine et al). 1999;66:602-8
Pariente-Khayat A, Tréluyer JM, Rey E, Mokhtari M, Werner E, Jouvet P, d'Athis P, Wood C, Hubert P, Hotellier F, olive G, Pons G. Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants. 1999;66:136-9
Parmelee T (*see* Yuan et al). 1999;66:9-15
Peck CC (*see* Atkinson et al). 1999;66:1
Pecquery R (*see* Alvarez et al). 1999;66:617-24
Pellizzoni C (*see* Denolle et al). 1999;66:282-7
Peraire C (*see* Barbanoj et al). 1999;66:485-91
Perez-Diaz F (*see* Alvarez et al). 1999;66:617-24
Pernerstorfer T, Schmid R, Bieglmayer C, Eichler HG, Kapiotis S, Jilma B. Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. 1999;66:51-7
Pershing LK (*see* Singh et al). 1999;66:346-57
Perucca E (*see* Volosov et al). 1999;66:547-53
Petry NM, Bickel WK, Badger GJ. A comparison of four buprenorphine dosing regiment in the treatment of opioid dependence. 1999;66:306-14
Poggesi I (*see* Denolle et al). 1999;66:282-7
Poirier JM (*see* Tennezé et al). 1999;66:582-8
Poloyac SM, Tosheva RT, Gardner BM, Shedlofsky SI, Blouin RA. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. 1999;66:554-62
Pons G (*see* Pariente-Khayat et al). 1999;66:136-9
Porras AG (*see* Rogers et al). 1999;66:358-66
Prange H (*see* Nau et al). 1999;66:25-32
Price R (*see* Simpson et al). 1999;66:474-84

Q

Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH. Effect of the gene dosage of *CYP2C19* on diazepam metabolism in Chinese subjects. 1999;66:642-6
Quak CME (*see* van Lingen et al). 1999;66:509-15
Quintin P (*see* Alvarez et al). 1999;66:617-24

R

Reidenberg J. The case of the forgotten author: a mystery to editors. 1999;66:333-5 (Commentary)
Reidenberg MM. Clinical pharmacology: the scientific basis of therapeutics. 1999;66:1-8 (Commentary) 1999;66:624 (Correction)
Rey E (*see* Pariente-Khayat et al). 1999;66:136-9
Rich B (*see* Hartung et al). 1999;66:415-24
Rigaudy L (*see* Kovarik et al). 1999;66:391-400
Rigby RJ (*see* Johnson et al). 1999;66:492-500
Rissanen AM (*see* Vidgren et al). 1999;66:315-22
Rogers HD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG, Blum RA, Wilson ME, Stepanavage M, Vega JM. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 1999;66:358-66
Romerio SC, Linder L, Haefeli WE. Neurokinin-1 receptor antagonist R116301 inhibits substance P–induced venodilation. 1999;66:522-7
Roots I (*see* Aynaciouglu et al). 1999;66:185-92
Roots I (*see* Johne et al). 1999;66:338-45
Roots I (*see* Sachse et al). 1999;66:431-8
Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. 1999;66:76-84
Rost KL (*see* Kovarik et al). 1999;66:391-400
Ruschen S (*see* Sachse et al). 1999;66:431-8

S

Sachse C (*see* Aynaciouglu et al). 1999;66:185-92
Sachse C, Ruschen S, Dettling M, Schley J, Bauer S, Muller-Oerlinghausen B, Roots I, Brockmöller J. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism. 1999;66:431-8

Saito T (*see* Tsuruoka et al). 1999;66:609-16
Sale ME (*see* Barbey et al). 1999;66:91-9
Sato T (*see* Takahashi et al). 1999;66:569-81
Satyavageeswaran S (*see* Mamidi et al). 1999;66:193-200
Scatnia JA (*see* Ball et al). 1999;66:288-94
Schley J (*see* Sachse et al). 1999;66:431-8
Schmid R (*see* Pernerstorfer et al). 1999;66:51-7
Schröder T (*see* Aynaciouglu et al). 1999;66:185-92
Schwartz JB (*see* Krecic-Shepard et al). 1999;66:40-50
Seward RL (*see* Holroyd and Seward). 1999;66:323-5
Shah VP (*see* Singh et al). 1999;66:346-57
Shangraw RE, Fisher DM. Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. 1999;66:380-90
Shedlofsky SI (*see* Poloyac et al). 1999;66:554-62
Shi J (*see* Barbey et al). 1999;66:91-9
Shimizu T (*see* Takahashi et al). 1999;66:569-81
Shimoyama Y (*see* Takahashi et al). 1999;66:569-81
Shioda N (*see* Takahashi et al). 1999;66:569-81
Shirai N (*see* Ikeda et al). 1999;66:265-74
Shirakawa K (*see* Tanigawara et al). 1999;66:528-34
Shoulson I (*see* Swanson et al). 1999;66:294-305
Simon B (*see* Hartung et al). 1999;66:415-24
Simpson JA, Price R, ter Kuile F, Teja-Isavatharm P, Nosten F, Chongsuphajaisiddhi T, Looareesuwan S, Aarons L, WHite NJ. Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. 1999;66:472-84
Sindrup SH, Madsen C, Brøsen K, Jensen TS. The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels. 1999;66:636-41
Singh GJP, Adams WP, Lesko LJ, Shah VP, Molzon JA, Williams RL, Pershing LK. Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. 1999;66:346-57
Sintov A (*see* Volosov et al). 1999;66:547-53
Skovlund E (*see* Breivik et al). 1999;66:625-35
Slimko J (*see* Krecic-Shepard et al). 1999;66:40-50
Solà R M (*see* Barbanoj et al). 1999;66:485-91
Spreux-Varoquaux O (*see* Alvarez et al). 1999;66:617-24
Stepanavage M (*see* Rogers et al). 1999;66:358-66
Streetman DS, Ellis RE, Nafziger AN, Leeder S, Gaedigk A, Gotschall R, Kearns GL, Bertino JS. Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping. 1999;66:535-41
Subramaniam S (*see* Mamidi et al). 1999;66:193-200
Sugimoto K (*see* Tsuruoka et al). 1999;66:609-16
Swan L (*see* Muir et al). 1999;66:85-90
Swanson J, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. 1999;66:294-305

T

Tainaka H (*see* Takahashi et al). 1999;66:569-81
Takahashi H, Sato T, Shimoyama Y, Shioda N, Shimizu T, Kubo S, Tamura N, Tainaka H, Yasumori T, Echizen H. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. 1999;66:569-81
Takashima M (*see* Ikeda et al). 1999;66:265-74
Tamura N (*see* Takahashi et al). 1999;66:569-81
Tan CM, Macdonald CJ, Chorazyczewski J, Burry AE, Feldman RD. Vandate stimulation of adenylyl cyclase: an index to tyrosine kinase vascular effects. 1999;66:275-81
Tanaka M (*see* Murayama et al). 1999;66:258-64
Tang BK (*see* Kalow et al). 1999;66:445-7 (Commentary)
Tangphao O, Chalon S, Moreno HT, Abiose AK, Blaschke TF, Hoffman BB. Heparin-induced vasodilation in human hand veins. 1999;66:232-8
Tanigawara Y, Aoyama N, Kita T, Shirakawa K, Komada F, Kasuga M, Okumura K. *CYP2C19* genotype–related efficacy of omeprazole for the treatment of infection caused by *Helicobacter pylori*. 1999;66:528-34
Tapanainen P (*see* Laine et al). 1999;66:602-8
Taylor PJ (*see* Johnson et al). 1999;66:492-500
Teja-Isavatharm P (*see* Simpson et al). 1999;66:474-84
Tennezé L, Verstuyft C, Becquemont L, Poirier JM, Wilkerson GR, Funck-Brentano C. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. 1999;66:582-8
ter Kuile F (*see* Simpson et al). 1999;66:474-84
Terada Y (*see* Murayama et al). 1999;66:258-64
Terakawa M (*see* Koizumi et al). 1999;66:501-8
Terzic A (*see* Waldman and Terzic). 1999;66:336-7 (Commentary)
Terzic A. New frontiers of cardioprotection. 1999;66:105-9 (Commentary)
Thomas C (*see* de Meijer et al). 1999;66:425-30
Thummel KE (*see* Kinirons et al). 1999;66:224-31
Tibboel D (*see* van Lingen et al). 1999;66:509-15
Tosheva RT (*see* Poloyac et al). 1999;66:554-62
Tothaflusi L (*see* Kalow et al). 1999;66:445-7
Totoritis MC (*see* Mould et al). 1999;66:246-57
Tréluyer JM (*see* Pariente-Khayat et al). 1999;66:136-9
Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. 1999;66:461-71
Tsuruoka S, Sugimoto K, Ohmori M, Kawaguchi A, Saito T, Fujimura A. Chronotherapy of high-dose 1,25-dihydroxyvitamin D_3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study. 1999;66:609-16

U

Uppoor RS (*see* Yuan et al). 1999;66:9-15
Uusitupa MIJ (*see* Vidgren et al). 1999;66:315-22

V

Vakkalanka SVS (*see* Mamidi et al). 1999;66:193-200
Vallès J (*see* Barbanoj et al). 1999;66:485-91
Valve RS (*see* Vidgren et al). 1999;66:315-22
van Agtmael MA, Gupta V, van der Graaf CAA, van Boxtel CJ. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. 1999;66:408-14
van Boxtel CJ (*see* van Agtmael et al). 1999;66:408-14
van der Graaf CAA (*see* van Agtmael et al). 1999;66:408-14
van Lingen RA, Deinum HT, Quak CME, Okken A, Tibboel D. Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants. 1999;66:509-15
Vega JM (*see* Rogers et al). 1999;66:358-66
Velez RL (*see* Tsunoda et al). 1999;66:461-71
Verbruggen B (*see* de Meijer et al). 1999;66:425-30
Verstuyft C (*see* Tennezé et al). 1999;66:582-8
Vidgren HM, Agren JJ, Valve RS, Karhunen LJ, Rissanen AM, Uusitupa MIJ. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. 1999;66:315-22
Villikka K, Kivistö KT, Mäenpää H, Joensuu H, Neuvonen PJ. Cytochrome P450–inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. 1999;66:589-93
Volk HD (*see* Hartung et al). 1999;66:415-24
Vollaard H (*see* de Meijer et al). 1999;66:425-30
Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxycarbazepine to healthy Chinese subjects. 1999;66:547-53

von Aulock S (*see* Hartung et al). 1999;66:415-24
von Moltke LL (*see* Tsunoda et al). 1999;66:461-71

W

Wainer IW (*see* Krecic-Shepard et al). 1999;66:40-50
Waldman SA, Terzic A. The Molecular Therapeutics Section of the American Society for Clinical Pharmacology and Therapeutics. 1999;66:336-7 (Commentary)
Wang JS (*see* Backman et al). 1999;66:401-7
Wang W (*see* Qin et al). 1999;66:642-6
Wang YJ (*see* Qin et al). 1999;66:642-6
Warner N (*see* Ball et al). 1999;66:288-94
Weinryb I (*see* Ball et al). 1999;66:288-94
Wen X (*see* Backman et al). 1999;66:401-7
Wendel A (*see* Hartung et al). 1999;66:415-24
Werner E (*see* Pariente-Khayat et al). 1999;66:136-9
Westerberg PA (*see* Mirghani et al). 1999;66:454-60
White NJ (*see* Simpson et al). 1999;66:474-84
Wigal S (*see* Swanson et al). 1999;66:294-305
Wilkinson GR (*see* Tennezé et al). 1999;66:582-8
Wilkinson RG (*see* Kinirons et al). 1999;66:224-31
Williams L (*see* Swanson et al). 1999;66:294-305
Williams RI (*see* Singh et al). 1999;66:346-57
Wilson MF (*see* Luzier et al). 1999;66:594-601
Wilson MF (*see* Rogers et al). 1999;66:358-66
Wilton JH (*see* Luzier et al). 1999;66:594-601
Wing YK (*see* Lam et al). 1999;66:647 (Letter)
Wood AJJJ (*see* Kinirons et al). 1999;66:224-31
Wood C (*see* Pariente-Khayat et al). 1999;66:136-9
Woosley RL (*see* Barbey et al). 1999;66:91-9

X

Xiaodong S (*see* Volosov et al). 1999;66:547-53
Xie HG (*see* Qin et al). 1999;66:642-6
Xu ZH (*see* Qin et al). 1999;66:642-6

Y

Yagen B (*see* Volosov et al). 1999;66:547-53
Yamada H (*see* Murayama et al). 1999;66:258-64
Yasumori T (*see* Takahashi et al). 1999;66:569-81
Yoshida H (*see* Ikeda et al). 1999;66:265-74
Yu L (*see* Gelal et al). 1999;66:123-35
Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, Marroum P. In vitro metabolic interaction studies: experience of the Food and Drug Administration. 1999;66:915

Z

Zhang YD (*see* Cai et al). 1999;66:516-21
Zhao J (*see* Rogers et al). 1999;66:358-66
Zhou Y (*see* Cai et al). 1999;66:516-21

Subject index

A

Abetimus sodium
Abetimus sodium (USAN List No. 422). 1999;66:653

Abortion
Mifepristone (USAN List No. 419). 1999;66:330

Acetaminophen
Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial (Pernerstorfer et al). 1999;66:51-7
Combination of diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study (Breivik et al). 1999;66:625-35
Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants (van Lingen et al). 1999;66:509-15

Adenosine triphosphate
New frontiers of cardioprotection (Terzic et al). 1999;66:105-9 (Commentary)

Adenylyl cyclase
Vandate stimulation of adenylyl cyclase: an index to tyrosine kinase vascular effects (Tan et al). 1999;66:275-81

Adrenergic beta-antagonists
Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects (Barbey et al). 1999;66:91-9

Aldose reductase inhibitor
Zenarestat (USAN List No. 420). 1999;66:443

Alleles
Association between *CYP2A6* and *CYP2C19* mutant alleles (Lam et al). 1999;66:647 (Letter)
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism (Sachse et al). 1999;66:431-8
Low frequency of defective alleles of cytochrome P450 enzymes 2C10 and 2D6 in the Turkish population (Aynacioglu et al). 1999;66:185-92

Altinicline maleate
Altinicline maleate (USAN List No. 422). 1999;66:650

Alzheimer's disease
Levosimendan (USAN List No. 418). 1999;66:207

American Society for Clinical Pharmacology and Therapeutics
ASCPT moves to Alexandria, Virginia. 1999;66:328
Future meeting dates and sites of the ASCPT. 1999;66:32
Nominations for awards. 1999;66:326-7, 542
Optimizing formulary decision making: core expertise for P & T committees. 1999;66:649
The Molecular Therapeutics Section of the American Society for Clinical Pharmacology and Therapeutics (Waldman and Terzic). 1999;66:336-7 (Commentary)
Welcome new ASCPT members. 1999;66:648

American Society for Pharmacology and Experimental Therapeutics
Cellular mechanisms and novel strategies for pain control: ASPET–Ray Fuller Symposium. 1999;66:100

Amyotrophic lateral sclerosis
Mecaserim (USAN List No. 419). 1999;66:331

Analgesics
Levobupivacaine hydrochloride (USAN List No. 417). 1999;66:104

Analgesics, non-narcotic
Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial (Pernerstorfer et al). 1999;66:51-7

Anesthetics, intravenous
Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study (Hamaoka et al). 1999;66:110-7

Angiotensin
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay (Belz et al). 1999;66:367-73

Anidulafungin
Anidulafungin (USAN List No. 422). 1999;66:654

Anti-anxiety agents, benzodiazepine
Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants (Pariente-Khayat et al). 1999;66:136-9

Anti-arrhythmia agents
Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects (Barbey et al). 1999;66:91-9

Anti-asthmatic agents
Edodekin alfa (USAN List No. 418). 1999;66:206

Anti-HIV agents
Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam (Palkama et al). 1999;66:33-9
Emitricitabine (USAN List No. 417). 1999;66:101
Pharmacokinetics of zidovudine in infants: a population analysis across studies (Mirochnick et al). 1999;66:16-24

Anti-inflammatory agents
Celecoxib (USAN List No. 418). 1999;66:205
Deracoxib (USAN List No. 418). 1999;66:208
Etanercept (USAN List No. 418). 1999;66:209
Nepafenac (USAN List No. 418). 1999;66:208
Parecoxib sodium (USAN List No. 419). 1999;66:331
Valdecoxib (USAN List No. 419). 1999;66:331

Anti-inflammatory agents, steroidal
Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study (Dandona et al). 1999;66:58-65

Anti-ulcer agents
Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance (Mathot et al).1999;66:140-51

July, pp. 1-104; August, pp. 105-210; September, pp. 211-332; October, pp. 333-444; November, pp. 445-546; December, pp. 547-674. Index to the ASCPT meeting abstracts is located in the February issue.

Anticholesteremic agents
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin (Lilija et al). 1999;66:118-27

Anticoagulants
Tifacogin (USAN List No. 421). 1999;66:543

Anticonvulsants
Cytochrome P450–inducing antiepileptics increase the clearance of vincristine in patients with brain tumors (Villikka et al). 1999;66:589-93

Antidepressive agents
Igmesine hydrochloride (USAN List No. 417). 1999;66:104

Antidepressive agents, tricyclic
Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics (Danish University Antidepressant Group). 1999;66:152-65

Antiepileptics; *see* Anticonvulsants

Antilipemic agents
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia (de la Serna et al). 1999;66:166-72

Antineoplastic agents
Biricodar dicitrate (USAN List No. 417). 1999;66:102
Satraplatin (USAN List No. 420). 1999;66:440

Antiviral agents
Maribavir (USAN List No. 419). 1999;66:329
Penciclovir sodium (USAN List No. 420). 1999;66:441
Saquinavir (USAN List No. 419). 1999;66:332
Tremacamra (USAN List No. 421). 1999;66:544

Artemether
The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects (van Agtmael et al). 1999;66:408-14

Aspirin
Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial (Pernerstorfer et al). 1999;66:51-7

Attention deficit hyperactivity disorder
Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children (Swanson et al). 1999;66:295-305

Authors
Omission of authors. 1999;66:333 (Commentary)
The case of the forgotten author: a mystery to editors (Reidenberg). 1999;66:333-5 (Commentary)

Axitirome
Axitirome (USAN List No. 422). 1999;66:655

B

Basiliximab
Basiliximab (USAN List No. 422). 1999;66:653

Benzbromarone
Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone (Takahashi et al). 1999;66:569-81

Beverages
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin (Lilija et al). 1999;66:118-27

Bexlosteride
Bexlosteride (USAN List No. 422). 1999;66:653

Binetrakin
Binetrakin (USAN List No. 422). 1999;66:650

Biricodar dicitrate
Biricodar dicitrate (USAN List No. 417). 1999;66:102

Body temperature
Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial (Pernerstorfer et al). 1999;66:51-7

Brain edema
Entry of tromethamine into the cerebrospinal fluid of humans after cerebrovascular events (Nau et al). 1999;66:25-32

Brasofensine maleate
Brasofensine maleate (USAN List No. 422). 1999;66:655

Buprenorphine
A comparison of four buprenorphine dosing regimens in the treat of opioid dependence (Petry et al). 1999;66:306-14

C

Caffeine
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism (Sachse et al). 1999;66:431-8

Cardiovascular diseases
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia (de la Serna et al). 1999;66:166-72
Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field (Nony et al). 1999;66:173-84

Caucasoid race
Low frequency of defective alleles of cytochrome P450 enzymes 2C10 and 2D6 in the Turkish population (Aynacioglu et al). 1999;66:185-92

Celecoxib
Celecoxib (USAN List No. 418). 1999;66:205

Cetuximab
Cetuximab (USAN List No. 422). 1999;66:654

Cerebrovascular disorders
Entry of tromethamine into the cerebrospinal fluid of humans after cerebrovascular events (Nau et al). 1999;66:25-32
Gavestinel (USAN List No. 417). 1999;66:103

Children
Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children (Swanson et al). 1999;66:295-305

Chinese
Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxycarbazepine to healthy Chinese subjects (Volosov et al). 1999;66:547-53
Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers (Cai et al). 1999;66:516-21

Chloroguanide
Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination (Tennezè et al). 1999;66:582-8

Chlorzoxazone
The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans (Poloyac et al). 1999;66:554-62

Cholesterol
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia (de la Serna et al). 1999;66:166-72

Chronotherapy
Chronotherapy of high-dose 1,25-dihydroxyvitamin D_3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study (Tsuruoka et al). 1999;66:609-16

Cirrhosis; *see* Liver cirrhosis

Cisapride
Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride (Kivistö et al). 1999;66:448-53

Citalopram hydrobromide
Citalopram hydrobromide (USAN List No. 422). 1999;66:656

Citrus
Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (Rogers et al). 1999;66:358-66
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin (Lilija et al). 1999;66:118-27
Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride (Kivistö et al). 1999;66:448-53
The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects (van Agtmael et al). 1999;66:408-14

Clarithromycin
Effects of clarithromycin on the metabolism of omeprazole in relation to *CYP2C19* genotype status in humans (Furuta et al). 1999;66:265-74

Clenoliximab
A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis (Mould et al). 1999;66:246-57

Clevudine
Clevudine (USAN List No. 422). 1999;66:656

Clinical Pharmacology and Therapeutics
Omission of authors. 1999;66:333 (Commentary)
The case of the forgotten author: a mystery to editors (Reidenberg). 1999;66:333-5 (Commentary)

Clomipramine
Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics (Danish University Antidepressant Group). 1999;66:152-65
Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine (Alvarez et al). 1999;66:617-24

Clozapine
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism (Sachse et al). 1999;66:431-8

Codeine
Combination of diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study (Breivik et al). 1999;66:625-35

Coenzyme A reductase inhibitors
Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (Rogers et al). 1999;66:358-66

Commentaries
Commentaries. 1999;66:1-8, 105-9, 211-23, 333-7, 445-7
The science of pharmacological variability: an essay (Kalow et al). 1999;66:445-7

Contraceptives, oral
Mifepristone (USAN List No. 419). 1999;66:330

Coronary vessels
Hemodynamic and coronary effects of intravenous eletriptan, a $5HT_{1B/1D}$-receptor agonist (Muir et al). 1999;66:85-90

Corrections
Clinical pharmacology: The scientific basis of therapeutics (Reidenberg) (1999;66:1-8). 1999;66:624 (Correction)
Analysis of the *CYP2D6* gene in relation to dextromethorphan *O*-demethylation capacity in a Japanese population (Tateishi et al) (1999;65:570-5). 1999;66:581 (Correction)

Corticosteroids
Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling (Singh et al). 1999;66:346-57

Cyclooxygenase-2 inhibitors
Celecoxib (USAN List No. 418). 1999;66:205
Parecoxib sodium (USAN List No. 419). 1999;66:331
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects (Rossat et al). 1999;66:76-84
Valdecoxib (USAN List No. 419). 1999;66:331

Cyclosporine
Developmental pharmacodynamics of cyclosporine (Marshall and Kearns). 1999;66:66-75

Cytochrome P450
Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination (Tennezè et al). 1999;66:582-8
Association between *CYP2A6* and *CYP2C19* mutant alleles (Lam et al). 1999;66:647 (Letter)
CYP2C19 genotype–related efficacy of omeprazole for the treatment of infection caused by *Helicobacter pylori* (Tanigawara et al). 1999;66:528-34
Cytochrome P450–inducing antiepileptics increase the clearance of vincristine in patients with brain tumors (Villikka et al). 1999;66:589-93
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole (Tsunoda et al). 1999;66:461-71
Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping (Streetman et al). 1999;66:535-41
Effect of the gene dosage of *CYP2C19* on diazepam metabolism in Chinese subjects (Qin et al). 1999;66:642-6
Effects of clarithromycin on the metabolism of omeprazole in relation to *CYP2C19* genotype status in humans (Furuta et al). 1999;66:265-74
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A (Kinirons et al). 1999;66:224-31
Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers (Cai et al). 1999;66:516-21
In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil (Krecic-Shepard et al). 1999;66:40-50
Low frequency of defective alleles of cytochrome P450 enzymes 2C10 and 2D6 in the Turkish population (Aynacioglu et al). 1999;66:185-92

Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam (Backman et al). 1999;66:401-7

Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of *CYP3A4* (Ball et al). 1999;66:288-94

Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study (Hamaoka et al). 1999;66:110-7

The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo (Mirghani et al). 1999;66:454-60

Cytokines

Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions (Hartung et al). 1999;66:415-24

Cytomegalovirus infections

Maribavir (USAN List No. 419). 1999;66:329

D

Depression, involutional

Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics (Danish University Antidepressant Group). 1999;66:152-65

Deracoxib

Deracoxib (USAN List No. 418). 1999;66:208

Dermatitis, atopic

Hydrocortisone probutate (USAN List No. 417). 1999;66:104

Dextromethorphan

Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination (Tennezè et al). 1999;66:582-8

Dose dependency of dextromethorphan for cytochrome P450 2D6 (CYP2D6) phenotyping (Streetman et al). 1999;66:535-41

In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil (Krecic-Shepard et al). 1999;66:40-50

Polymorphism of dextromethorphan oxidation in South Indian subjects (Mamidi et al). 1999;66:193-200

Diabetes mellitus

Mecaserim (USAN List No. 419). 1999;66:331

Voglibose (USAN No. 420). 1999;66:444

Diazepam

Effect of the gene dosage of *CYP2C19* on diazepam metabolism in Chinese subjects (Qin et al). 1999;66:642-6

Dichloroacetate

Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis (Shangraw and Fisher). 1999;66:380-90

Diclofenac

Combination of diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study (Breivik et al). 1999;66:625-35

Digoxin

Longitudinal assessment of a P-glycoprotein–mediated drug interaction of valspodar on digoxin (Kovarik et al). 1999;66:391-400

Pharmacokinetic interaction of digoxin with a herbal extract from St John's wort (*Hypericum perforatum*) (Johne et al). 1999;66:338-45

Doxercalciferol

Doxercalciferol (USAN List No. 422). 1999;66:655

Drug interactions

In vitro metabolic interaction studies: experience of the Food and Drug Administration (Yuan et al). 1999;66:9-15

Drug screening

In vitro metabolic interaction studies: experience of the Food and Drug Administration (Yuan et al). 1999;66:9-15

Dutasteride

Dutasteride (USAN List No. 417). 1999;66:101

DX-9065a

Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers (Murayama et al). 1999;66:258-64

E

Edodekin alfa

Edodekin alfa (USAN List No. 418). 1999;66:206

Education, medical

Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field (Nony et al). 1999;66:173-84

Emitricitabine

Emitricitabine (USAN List No. 417). 1999;66:101

Endotoxin

The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans (Poloyac et al). 1999;66:554-62

Erythromycin

Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A (Kinirons et al). 1999;66:224-31

In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil (Krecic-Shepard et al). 1999;66:40-50

Etanercept

Etanercept (USAN List No. 418). 1999;66:209

Evidence-based medicine

Clinical pharmacology: The scientific basis of therapeutics (Reidenberg) (1999;66:1-8). 1999;66:624 (Correction)

Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field (Nony et al). 1999;66:173-84

F

Fatty acids

The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects (Vidgren et al). 1999;66:315-22

Fever

Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial (Pernerstorfer et al). 1999;66:51-7

Fibrinogen

Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia (de la Serna et al). 1999;66:166-72

Filgrastim
Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions (Hartung et al). 1999;66:415-24

FK 706
Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK 706 (Koizumi et al). 1999;66:501-8

Flavin monooxygenase 3
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism (Sachse et al). 1999;66:431-8

Flunitrazepam
Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants (Pariente-Khayat et al). 1999;66:136-9

Fluoxetine
Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine (Alvarez et al). 1999;66:617-24
Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers (Cai et al). 1999;66:516-21

G

Gavestinel
Gavestinel (USAN List No. 417). 1999;66:103

Gender
Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers (Luzier et al). 1999;66:594-601

Grapefruit juice; *see* Citrus

H

Heart failure, congestive
Levosimendan (USAN List No. 418). 1999;66:207
Nepicastat hydrochloride (USAN List No. 420). 1999;66:440
Nesiritide (USAN List No. 420). 1999;66:441

Heart rate
Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects (Barbey et al). 1999;66:91-9
Pharmacokinetics and tolerance of flunitrazepam in neonates and in infants (Pariente-Khayat et al). 1999;66:136-9

Heflicon A
Heflicon A (USAN List No. 418). 1999;66:207

Heflicon B
Heflicon B (USAN List No. 418). 1999;66:207

Heflicon C
Heflicon C (USAN List No. 418). 1999;66:207

Helicobacter pylori
CYP2C19 genotype–related efficacy of omeprazole for the treatment of infection caused by *Helicobacter pylori* (Tanigawara et al). 1999;66:528-34

Hemodialysis
Chronotherapy of high-dose 1,25-dihydroxyvitamin D_3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study (Tsuruoka et al). 1999;66:609-16

Hemodynamics
Hemodynamic and coronary effects of intravenous eletriptan, a $5HT_{1B/1D}$-receptor agonist (Muir et al). 1999;66:85-90

Heparin
Heparin-induced vasodilation in human hand veins (Tangphao et al). 1999;66:232-8

Hepatitis B virus
Emitricitabine (USAN List No. 417). 1999;66:101

Herpes virus infections
Penciclovir sodium (USAN List No. 420). 1999;66:441

Histamine H2 antagonists
Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance (Mathot et al).1999;66:140-51

HIV infections
Pharmacokinetics of zidovudine in infants: a population analysis across studies (Mirochnick et al). 1999;66:16-24

Hormone replacement therapy
Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy (Laine et al). 1999;66:602-8

Hydrocortisone probutate
Hydrocortisone probutate (USAN List No. 417). 1999;66:104

Hydroxylases
In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil (Krecic-Shepard et al). 1999;66:40-50
Low frequency of defective alleles of cytochrome P450 enzymes 2C10 and 2D6 in the Turkish population (Aynacioglu et al). 1999;66:185-92

Hydroxymethylglutaryl-CoA reductase inhibitors
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin (Lilija et al). 1999;66:118-27

Hyperbilirubinemia
Stannsoporfin (USAN List No. 421). 1999;66:544

Hyperparathyroidism
Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination (Tennezè et al). 1999;66:582-8

Hypertension
Omapatrilat (USAN List No. 420). 1999;66:441

Hypoglycemic agents
Insulin aspart (USAN List No. 417). 1999;66:103

I

Igmesine hydrochloride
Igmesine hydrochloride (USAN List No. 417). 1999;66:104

Ilomastat
Ilomastat(USAN List No. 418). 1999;66:209

Immunosuppressive agents
Developmental pharmacodynamics of cyclosporine (Marshall and Kearns). 1999;66:66-75

Mycophenolate mofetil hydrochloride (USAN List No. 417). 1999;66:102

Indoles
Hemodynamic and coronary effects of intravenous eletriptan, a $5HT_{1B/1D}$-receptor agonist (Muir et al). 1999;66:85-90

Infants
Multiple-dose pharmacokinetics of rectally administered acetaminophen in term infants (van Lingen et al). 1999;66:509-15

Inositol triphosphate
Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine (Alvarez et al). 1999;66:617-24

Insulin
Insulin aspart (USAN List No. 417). 1999;66:103

Interleukin-10
Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study (Dandona et al). 1999;66:58-65

Intracranial pressure
Entry of tromethamine into the cerebrospinal fluid of humans after cerebrovascular events (Nau et al). 1999;66:25-32

Irbesartan
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay (Belz et al). 1999;66:367-73

Ischemic preconditioning, myocardial
New frontiers of cardioprotection (Terzic et al). 1999;66:105-9 (Commentary)

Isoenzymes
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects (Rossat et al). 1999;66:76-84

Isradipine
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam (Backman et al). 1999;66:401-7

K

Ketoconazole
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole (Tsunoda et al). 1999;66:461-71
Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans (Herman et al). 1999;66:374-9

Kidney
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects (Rossat et al). 1999;66:76-84

Kidney failure
Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency (Barbanoj et al). 1999;66:485-91

Kidney transplantation
The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients (Johnson et al). 1999;66:492-50

L

Lanreotide
Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency (Barbanoj et al). 1999;66:485-91

Leridistim
Leridistim (USAN List No. 421). 1999;66:545

Leteprinim potassium
Leteprinim potassium (USAN List No. 418). 1999;66:206

Letters
Association between *CYP2A6* and *CYP2C19* mutant alleles (Lam et al). 1999;66:647
Dosing recommendations in liver disease (Bergquist et al). 1999;66:201-4

Leukocytes
Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study (Dandona et al). 1999;66:58-65

Levobupivacaine hydrochloride
Levobupivacaine hydrochloride (USAN List No. 417). 1999;66:104

Levosimendan
Levosimendan (USAN List No. 418). 1999;66:207

Liver cirrhosis
Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis (Shangraw and Fisher). 1999;66:380-90

Liver diseases
Dosing recommendations in liver disease (Bergquist et al). 1999;66:201-4 (Letter)

Lobradimil
Lobradimil (USAN List No. 419). 1999;66:329

Losartan
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay (Belz et al). 1999;66:367-73

Lymphocytes
Effect of filgrastim treatment on inflammatory cytokines and lymphocyte functions (Hartung et al). 1999;66:415-24

M

Malaria
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria (Simpson et al). 1999;66:472-84
The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects (van Agtmael et al). 1999;66:408-14

Mangafodipir trisodium
Mangafodipir trisodium (USAN List No. 418). 1999;66:205

Maribavir
Maribavir (USAN List No. 419). 1999;66:329

Mecaserim
Mecaserim (USAN List No. 419). 1999;66:331

Mefloquine
Population pharmacokinetics of mefloquine in patients with acute falciparum malaria (Simpson et al). 1999;66:472-84

Meloxicam
Meloxicam, 15 mg/day, spares platelet function in healthy volunteers (De Meijer et al). 1999;66:425-30

Menthol
Disposition kinetics and effects of menthol (Gelal et al). 1999;66:128-35

Methylphenidate
Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children (Swanson et al). 1999; 66:295-305

Metoprolol
Gender-related effects on metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers (Luzier et al). 1999;66: 594-601

Mibefradil
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam (Backman et al). 1999;66:401-7

Midazolam
Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole (Tsunoda et al). 1999;66:461-71
Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam (Palkama et al). 1999;66:33-9
Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A (Kinirons et al). 1999;66:224-31
Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study (Hamaoka et al). 1999; 66:110-7

Mifepristone
Mifepristone (USAN List No. 419). 1999;66:330

Mitumomab
Mitumomab (USAN List No. 422). 1999;66:656

Moxifloxacin hydrochloride
Moxifloxacin hydrochloride (USAN List No. 418). 1999;66:208

Mutation
Low frequency of defective alleles of cytochrome P450 enzymes 2C10 and 2D6 in the Turkish population (Aynacioglu et al). 1999;66:185-92

Mycophenolate mofetil hydrochloride
Mycophenolate mofetil hydrochloride (USAN List No. 417). 1999;66:102

Mycophenolic acid
The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients (Johnson et al). 1999;66:492-50

N

Nelarabine
Nelarabine (USAN List No. 422). 1999;66:654

Nepafenac
Nepafenac (USAN List No. 418). 1999;66:208

Nepicastat hydrochloride
Nepicastat hydrochloride (USAN List No. 420). 1999;66:440

Nesiritide
Nesiritide (USAN List No. 420). 1999;66:441

O

Obesity
The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects (Vidgren et al). 1999;66:315-22

Omapatrilat
Omapatrilat (USAN List No. 420). 1999;66:441

Omeprazole
CYP2C19 genotype–related efficacy of omeprazole for the treatment of infection caused by *Helicobacter pylori* (Tanigawara et al). 1999;66:528-34
Effects of clarithromycin on the metabolism of omeprazole in relation to *CYP2C19* genotype status in humans (Furuta et al). 1999;66:265-74

Opioids
A comparison of four buprenorphine dosing regimens in the treat of opioid dependence (Petry et al). 1999;66:306-14

Oral surgery; *see* Tooth extraction

Orlistat
The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects (Vidgren et al). 1999;66:315-22

Osteodystrophy
Paricalcitol (USAN List No. 421). 1999;66:543

Oxycarbazepine
Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxycarbazepine to healthy Chinese subjects (Volosov et al). 1999;66:547-53

P

P-glycoprotein
Longitudinal assessment of a P-glycoprotein–mediated drug interaction of valspodar on digoxin (Kovarik et al). 1999;66: 391-400

Paflufocon
Paflufocon (USAN No. 422). 1999;66:651.

Parecoxib sodium
Parecoxib sodium (USAN List No. 419). 1999;66:331

Paricalcitol
Paricalcitol (USAN List No. 421). 1999;66:543

Penciclovir sodium
Penciclovir sodium (USAN List No. 420). 1999;66:441

Pexiganan acetate
Pexiganan acetate (USAN List No. 419). 1999;66:330

Pharmaceutical preparations
In vitro metabolic interaction studies: experience of the Food and Drug Administration (Yuan et al). 1999;66:9-15

Pharmacology, clinical
A flight through clinical pharmacology: it's great to soar with the eagles (Lemberger). 1999;66:218-23 (Commentary)
Clinical pharmacology: The scientific basis of therapeutics (Reidenberg) (1999;66:1-8). 1999;66:624 (Correction)
Dr Marcus M. Reidenberg, recipient of the 1999 Harry Gold Award (Atkinson et al). 1999;66:1 (Commentary)

Phenytoin
Ticlopidine inhibits phenytoin clearance (Donahue et al). 1999;66:563-68

Platelets
Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine (Alvarez et al). 1999;66:617-24
Meloxicam, 15 mg/day, spares platelet function in healthy volunteers (De Meijer et al). 1999;66:425-30

Polymorphism (genetic)
Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism (Sachse et al). 1999;66:431-8
Polymorphism of dextromethorphan oxidation in South Indian subjects (Mamidi et al). 1999;66:193-200

Polyneuropathy
The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels (Sindrup et al). 1999;66:636-41

Porphyria
Psychotropic drugs in acute intermittent porphyria (Holroyd and Seward). 1999;66:323-5

Potassium channels
New frontiers of cardioprotection (Terzic et al). 1999;66:105-9 (Commentary)

Pramlintide acetate
Pramlintide acetate (USAN List No. 419). 1999;66:332

Prescriptions, drug
Implication of evidence-based medicine in prescription guidelines taught to French medical students: current status in the cardiovascular field (Nony et al). 1999;66:173-84

Probutate
Probutate (USAN List No. 417). 1999;66:103

Procetofen
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia (de la Serna et al). 1999;66:166-72

Propafenone
Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers (Cai et al). 1999;66:516-21

Propofol
Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study (Hamaoka et al). 1999;66:110-7

Prostaglandin-endoperoxide synthase
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects (Rossat et al). 1999;66:76-84

Prostatic hyperplasia
Dutasteride (USAN List No. 417). 1999;66:101

Psychotropic drugs
Psychotropic drugs in acute intermittent porphyria (Holroyd and Seward). 1999;66:323-5

Pyrroles
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin (Lilija et al). 1999;66:118-27

Pyrrolidines
Hemodynamic and coronary effects of intravenous eletriptan, a $5HT_{1B/1D}$-receptor agonist (Muir et al). 1999;66:85-90

Q

Quinine
The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo (Mirghani et al). 1999;66:454-60

R

R116301
Neurokinin-1 receptor antagonist R116301 inhibits substance P–induced venodilation (Romerio et al). 1999;66:522-7

Ranitidine
Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance (Mathot et al).1999;66:140-51

Reactive oxygen species
Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study (Dandona et al). 1999;66:58-65

Reboxetine
Hemodynamic effects of reboxetine in healthy male volunteers (Denolle et al). 1999;66:282-7
Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans (Herman et al). 1999;66:374-9

Reboxetine mesylate
Reboxetine mesylate (USAN List No. 419). 1999;66:330

Renal insufficiency; *see* Renal failure

Research
Statistical reductionism and clinicians' delinquencies in humanistic research (Feinstein). 1999;66:211-8 (Commentary)

Rheumatoid arthritis
A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis (Mould et al). 1999;66:246-57

S

Sacrosidase
Sacrosidase (USAN List No. 420). 1999;66:442

Saquinavir
Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam (Palkama et al). 1999;66:33-9
Saquinavir (USAN List No. 419). 1999;66:332

Satraplatin
Satraplatin (USAN List No. 420). 1999;66:440

Sedatives, nonbarbiturate
Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam (Palkama et al). 1999;66:33-9

Semparatide acetate
Semparatide acetate (USAN List No. 421). 1999;66:545

Serotonin
Decreased platelet serotonin transporter sites and increased platelet inositol triphosphate levels in patients with unipolar depression: effects of clomipramine and fluoxetine (Alvarez et al). 1999;66:617-24

Serotonin agonists
Hemodynamic and coronary effects of intravenous eletriptan, a $5HT_{1B/1D}$-receptor agonist (Muir et al). 1999;66:85-90

Serotonin uptake inhibitors
Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics (Danish University Antidepressant Group). 1999;66:152-65

Smoking
Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK 706 (Koizumi et al). 1999;66:501-8

Sodium
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects (Rossat et al). 1999;66:76-84

Sodium dichloroacetate
Sodium dichloroacetate (USAN List No. 419). 1999;66:332

Sonepirazole mesylate
Sonepirazole mesylate (USAN List No. 420). 1999;66:442

Sotalol
Pharmacokinetic, pharmacodynamic, and safety evaluation of an accelerated dose titration regimen of sotalol in healthy middle-aged subjects (Barbey et al). 1999;66:91-9

St John's wort
Pharmacokinetic interaction of digoxin with a herbal extract from St John's wort (*Hypericum perforatum*) (Johne et al). 1999;66:338-45

Stannsoporfin
Stannsoporfin (USAN List No. 421). 1999;66:544

Statistics
Statistical reductionism and clinicians' delinquencies in humanistic research (Feinstein). 1999;66:211-8 (Commentary)

Stroke; *see* Cerebrovascular disorders

Substance abuse
A comparison of four buprenorphine dosing regimens in the treat of opioid dependence (Petry et al). 1999;66:306-14

Substance P
Neurokinin-1 receptor antagonist R116301 inhibits substance P–induced venodilation (Romerio et al). 1999;66:522-7

Sulfonamides
Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects (Rossat et al). 1999;66:76-84

T

Tacrine
Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy (Laine et al). 1999;66:602-8

Talinolol
Intestinal secretion of intravenous talinolol is inhibited by luminal *R*-verapamil (Gramatté et al). 1999;66:239-45

Tenecteplase
Tenecteplase (USAN No. 422). 1999;66:652.

Terbogrel
Terbogrel (USAN List No. 420). 1999;66:442

Therapeutics
Clinical pharmacology: The scientific basis of therapeutics (Reidenberg) (1999;66:1-8). 1999;66:624 (Correction)

Thrombocytopenia
Leridistim (USAN List No. 421). 1999;66:545

Ticlopidine
Ticlopidine inhibits phenytoin clearance (Donahue et al). 1999;66:563-68

Tifacogin
Tifacogin (USAN List No. 421). 1999;66:543

Timcodar dimesylate
Timcodar dimesylate (USAN List No. 421). 1999;66:546

Tolterodine tartrate
Tolterodine tartrate (USAN No. 420). 1999;66:443

Tooth extraction
Combination of diclofenac with acetaminophen or acetaminophen-codeine after oral surgery: a randomized, double-blind single-dose study (Breivik et al). 1999;66:625-35

Tramadol
The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels (Sindrup et al). 1999;66:636-41

Travoprost
Travoprost (USAN No. 420). 1999;66:443

Trecetilide fumarate
Trecetilide fumarate (USAN No. 420). 1999;66:444

Tremacamra
Tremacamra (USAN List No. 421). 1999;66:544

Triglycerides
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia (de la Serna et al). 1999;66:166-72

Tromethamine
Entry of tromethamine into the cerebrospinal fluid of humans after cerebrovascular events (Nau et al). 1999;66:25-32

Tyrosine kinase
Vandate stimulation of adenylyl cyclase: an index to tyrosine kinase vascular effects (Tan et al). 1999;66:275-81

U

United States Adopted Names Council
USAN Council. 1999;66:101-4, 205-9, 329-32, 440-4, 543-6, 650-6

Uric acid
Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia (de la Serna et al). 1999;66:166-72

Urinary incontinence
Tolterodine tartrate (USAN No. 420). 1999;66:443

V

Valdecoxib
Valdecoxib (USAN List No. 419). 1999;66:331

Valsartan
Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay (Belz et al). 1999;66:367-73

Valspodar
Longitudinal assessment of a P-glycoprotein–mediated drug interaction of valspodar on digoxin (Kovarik et al). 1999;66:391-400

Vandate
Vandate stimulation of adenylyl cyclase: an index to tyrosine kinase vascular effects (Tan et al). 1999;66:275-81

Vasodilation
Heparin-induced vasodilation in human hand veins (Tangphao et al). 1999;66:232-8

Veins
Heparin-induced vasodilation in human hand veins (Tangphao et al). 1999;66:232-8

Venous dilation
Neurokinin-1 receptor antagonist R116301 inhibits substance P–induced venodilation (Romerio et al). 1999;66:522-7

Verapamil
In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil (Krecic-Shepard et al). 1999;66:40-50
Intestinal secretion of intravenous talinolol is inhibited by luminal *R*-verapamil (Gramatté et al). 1999;66:239-45

Vincristine
Cytochrome P450–inducing antiepileptics increase the clearance of vincristine in patients with brain tumors (Villikka et al). 1999;66:589-93

Vitamin D
Chronotherapy of high-dose 1,25-dihydroxyvitamin D_3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study (Tsuruoka et al). 1999;66:609-16

Voglibose
Voglibose (USAN No. 420). 1999;66:444

W

Warfarin
Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone (Takahashi et al). 1999;66:569-81

Z

Zenarestat
Zenarestat (USAN List No. 420). 1999;66:443

Ziconotide
Ziconotide (USAN List No. 421). 1999;66:545

Zidovudine
Pharmacokinetics of zidovudine in infants: a population analysis across studies (Mirochnick et al). 1999;66:16-24